Lasa Supergenerics Reports Mixed Financial Performance
Lasa Supergenerics, a microcap pharmaceutical company, has reported a decline in net sales and profit in the quarter ended September 2023. However, the company's EPS has increased, indicating higher profitability for shareholders. Investors should carefully consider the company's financial performance before making any investment decisions.
Lasa Supergenerics, a microcap pharmaceutical company, recently announced its financial results for the quarter ended September 2023. The company's stock has been given a 'Sell' call by MarketsMOJO.
According to the quarterly analysis, Lasa Supergenerics has seen a decline in its net sales by -20.48% compared to the previous quarter. The standalone net profit has also decreased by 99.60% in the same period. The operating profit (PBDIT) excluding other income has seen a significant decline of -74.32%, while the interest has increased by 51.35%.
The company's operating profit margin (excluding other income) has also fallen in the quarter ended September 2023 compared to the previous quarter. Overall, Lasa Supergenerics has shown negative financial performance in this quarter, with a score of -7, a significant decrease from 4 in the last three months.
However, there are some positive aspects to the company's financials. The earnings per share (EPS) for the quarter have been the highest in the last five quarters, indicating an increase in profitability and higher earnings for shareholders.
On the other hand, there are also some areas of concern for Lasa Supergenerics. The net sales for the quarter have fallen by -27.81% compared to the same period last year, and the profit after tax (PAT) for the nine months has also decreased by -20.72%. The net sales for the quarter have been the lowest in the last five quarters, showing a negative trend in the near term.
In conclusion, Lasa Supergenerics has shown a mixed performance in the quarter ended September 2023, with some positive and negative aspects. Investors should carefully analyze the company's financials before making any investment decisions.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
